CHICAGO (Reuters) - Avandia, GlaxoSmithKline Plc's widely used drug for treating type 2 diabetes, raises the risk of heart death by 64 percent and the risk of heart attack by 43 percent, U.S. researchers said on Monday.
The news about Avandia, a $3 billion a year drug also known as rosiglitazone, triggered a free fall in GSK's shares, which closed off more than 5 percent on the London Stock Exchange. The slide continued on the New York Stock Exchange, with shares falling more than 8 percent.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
